RPx therapies are engineered using a proprietary HSV-1 strain and immune activating transgenes to maximize T cell stimulation and systemic immune activation. The RPx platform uses a live, attenuated virus (HSV-1) that has been genetically modified to enable selective replication in tumor cells resulting in tumor killing while sparing normal cells, with a tolerable safety profile.
RP1 is a tumor directed oncolytic immunotherapy designed to treat more immune responsive tumor types and is currently being studied for the treatment of melanoma, NMSC, MSI-H, NSCLC, CSCC and CSCC organ transplant.
Publications & Presentation
RP2, which in addition to the genomic modifications found in RP1 it encodes an anti-CTLA-4 antibody, has been optimally designed to treat more immunologically silent tumors, such as solid tumors.
RP3, additionally expresses a pair of immune costimulatory pathway activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically ‘cold’ tumors.
Learn more about how our tumor-directed oncolytic immunotherapies work
For more information on our full pipeline click here.
Replimune is conducting trials designed to evaluate the safety and effectiveness of our investigational therapies in a range of solid tumors as single agents and combination with other immunotherapies. Learn more about our current trials here.